Abstract: [Abstract]: Objective: To construct a novel DC vaccine which can coexpressing suppressor of cytokine signaling 1 (SOCS1) inhibitor, high mobility group proteins B1 (HMGB1), and tumor-associated antigens. Method: First construct the plasmid （p/shS1-NY-IRES-sig-HMG B1）that coexpress SOCS1 inhibitor, HMGB1, and tumor associated antigens. Then p/shS1-NY-IRES-sig-HMGB1 was transfected into DC. PCR and western blot was used to verify the expression of the p/shS1-NY-IRES-sig-HMGB1. ELISA was used to analyze the variation of TNF-α、IL-12、IL-1 and IL-6. Result: The sequence of the plasmid coincided with the sequence that expected. NY-ESO-1 can be expressed correctly. HMGB1 can be express in the cytoplasm. SOCS1 can be silenced by SOCS1 shRNA plasmid shS. TNF-α、IL-12、IL-1 and IL-6 was up-regulated in the culture medium（p＜0.05）. Conclusion: Successfully construct a novel DC vaccine which can coexpressing SOCS1 inhibitor, HMGB1, and tumor-associated antigens.

Key words: SOCS1, HMGB1, plasmid, DC vaccine